Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.

Abstract: The present disclosure provides TGF? inhibitor therapy for treating immunosuppressive conditions, such as cancer. Selection of suitable therapy and patients who are likely to benefit from such therapy are also disclosed, as well as methods of treating cancer and methods of predicting and monitoring therapeutic response. Related compositions, methods and therapeutic use are also disclosed.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Abstract: Disclosed herein are LRRC33 inhibiting agents and related methods and uses thereof. More specifically, therapeutic agents for inhibiting LRRC33 effects in vivo are provided. Such agents are useful for the treatment of various disorders involving cells expressing LRRC33 or LRRC33-containing complexes on the surface of cells.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.

Abstract: The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.

Abstract: The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

Abstract: The invention relates to pharmaceutical combination product comprising (i) a MET inhibitor and (ii) an FGFR inhibitor, or a pharmaceutical acceptable salt thereof, respectively, or a prodrug thereof, respectively, and at least one pharmaceutically acceptable carrier.

Abstract: The present invention provides novel biomarkers, and methods of using said biomarkers, for assessing the efficacy of a treatment regimen for treating cancer in a subject, particularly for treating cancer via Hsp90 inhibition. The present invention also provides methods of identifying test agents capable of treating cancer, particularly in the case of cancers characterized by high levels of IL-8.

Abstract: The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

Abstract: The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

Abstract: The present invention provides novel biomarkers, and methods of using said biomarkers, for assessing the efficacy of a treatment regimen for treating cancer in a subject, particularly for treating cancer via Hsp90 inhibition. The present invention also provides methods of identifying test agents capable of treating cancer, particularly in the case of cancers characterized by high levels of IL-8.

Abstract: A genetic locus associated with asthma is identified. The genes within the locus, ASTH1I and ASTH1J, and the regulatory sequences of the locus are characterized. The genes are used to produce the encoded proteins; in screening for compositions that modulate the expression or function of ASTH1 proteins; and in studying associated physiological pathways. The DNA is further used as a diagnostic for genetic predisposition to asthma.